Multiple immune and stromal cell surface receptors and endocytic uptake pathways

The term "Multiple immune and stromal cell surface receptors and endocytic uptake pathways" refers to the complex, multi-factorial target profile of glatiramer acetate (Copaxone), a synthetic polymer used in the treatment of multiple sclerosis. Rather than hitting a single protein, this therapeutic approach involves broad interactions with various cell surface molecules, including Major Histocompatibility Complex (MHC) class II molecules and T-cell receptors, as well as various endocytic pathways on both immune cells (like macrophages and T cells) and stromal cells. By binding to these multiple receptors, the drug acts as a competitive inhibitor or decoy for myelin-reactive T cells, effectively shifting the immune response from a pro-inflammatory Th1 state to an anti-inflammatory Th2/Th3 state. This broad mechanism helps reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis by preventing the immune system from attacking the myelin sheath. Because it targets a wide array of surface proteins and uptake mechanisms, it is often classified in pharmacological databases under this descriptive, multi-target heading.

Other names

Glatiramer acetate target profileCop-1 targetsMHC class II and associated surface receptors

Glatiramer acetate acts as a decoy for myelin basic protein (MBP), binding to MHC class II molecules on antigen-presenting cells to modulate T-cell responses and induce regulatory Th2/Th3 cells.